News
WVE
6.14
+4.42%
0.26
Wave Life Sciences’ WVE-006 Advancements: A Buy Rating on Gene Editing Innovations and Strategic Partnerships
TipRanks · 4d ago
Buy Rating Affirmed: Wave Life Sciences’s Promising Future with Clinical Milestones and Strategic GSK Partnership
TipRanks · 4d ago
Wave Life Sciences Announces Approval Of First Clinical Trial Application For RestorAATion-2 Trial Of WVE-006 In Individuals With Alpha-1 Antitrypsin Deficiency
Wave Life Sciences Ltd. Announced the approval of its first clinical trial application for its RestorAATion-2 clinical trial of WVE-006. The company's first-in-class RNA editing oligonucleotide is being developed for the treatment of alpha-1 antitrypsin deficiency.
Benzinga · 5d ago
WAVE LIFE SCIENCES LTD: REMAINS ON TRACK TO DELIVER PROOF-OF-MECHANISM DATA, AS MEASURED BY RESTORATION OF M-AAT PROTEIN IN SERUM, IN 2024
Reuters · 5d ago
Analysts’ Top Healthcare Picks: AbbVie (ABBV), Wave Life Sciences (WVE)
TipRanks · 6d ago
Weekly Report: what happened at WVE last week (0422-0426)?
Weekly Report · 6d ago
Buy Rating Affirmed: Strategic Partnerships and Clinical Milestones Propel Wave Life Sciences’ Growth Potential
TipRanks · 04/26 06:16
Wave Life Sciences: A Promising Buy Rating Based on Strategic GSK Collaboration and Innovative siRNA Platform
TipRanks · 04/26 06:11
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise gets EU orphan drug status for muscular dystrophy drug. Edgewise Therapeutics has received orphan drug designation from EU regulators for its drug candidate sevasemten. The drug candidate is in the treatment of Becker muscular dy Strophy and Duchenne muscular dystrophy.
Seeking Alpha · 04/23 14:29
As Part Of Wave Life Sciences' Ongoing Collaboration With GSK, GSK Has Selected Its First Two Oligonucleotide Programs, GSK Will Provide An Initiation Payment Of $12M
GSK has selected the first two programs to advance to next phase of research collaboration with Wave. GSK says programs utilize Wave's next generation GalNAc-siRNA format with potential for best-in-class potency and durability. Wave is on track to initiate a clinical trial of its obesity program in 1Q 2025.
Benzinga · 04/23 14:22
WAVE LIFE SCIENCES LTD: WAVE IS ON TRACK TO INITIATE A CLINICAL TRIAL OF ITS WHOLLY OWNED INHBE PROGRAM FOR OBESITY IN 1Q 2025
Reuters · 04/23 12:30
WAVE LIFE SCIENCES ANNOUNCES CONTINUED MOMENTUM IN GSK COLLABORATION AND ADVANCEMENTS IN SIRNA AND RNA EDITING
Reuters · 04/23 12:30
Weekly Report: what happened at WVE last week (0415-0419)?
Weekly Report · 04/22 09:52
Weekly Report: what happened at WVE last week (0408-0412)?
Weekly Report · 04/15 09:49
Weekly Report: what happened at WVE last week (0401-0405)?
Weekly Report · 04/08 09:50
GRIN, WOOF and MRNS are among after hour movers
On the Move GRIN, WOOF and MRNS are among after hour movers. Candel Therapeutics (CADL) and Petco Health and Wellness Company (WOOF) gain. HWH International (HWH) is among the losers.
Seeking Alpha · 04/04 21:29
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Orgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. AN2 Therapeutics (NASdaq:ANTX) shares rose by 6.76%. Candel Therapeutic stock moved upwards by 4.99% during the day. Losers AcordaTherapeutics and WAVE Life Sciences lost 8.9% and 7.1% respectively.
Benzinga · 04/04 20:31
Wave Life Sciences Price Target Maintained With a $17.00/Share by Truist Securities
Dow Jones · 04/01 13:18
Truist Securities Reiterates Buy on WAVE Life Sciences, Maintains $17 Price Target
Benzinga · 04/01 13:08
Analysts’ Top Healthcare Picks: Wave Life Sciences (WVE), Passage Bio (PASG)
TipRanks · 04/01 11:21
More
Webull provides a variety of real-time WVE stock news. You can receive the latest news about Wave Life Scienc through multiple platforms. This information may help you make smarter investment decisions.
About WVE
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).